



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

FGTI-2734

Cat. No.: HY-128350
CAS No.: 1247018-19-4
Molecular Formula: C₂₆H₃₁FN₆O₂S
Molecular Weight: 510.63
Target: Farnesyl Transferase
Pathway: Metabolic Enzyme/Protease
Storage: 4°C, stored under nitrogen
 * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (97.92 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.9584 mL	9.7918 mL	19.5837 mL
		5 mM		0.3917 mL	1.9584 mL	3.9167 mL
		10 mM		0.1958 mL	0.9792 mL	1.9584 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 7.5 mg/mL (14.69 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC ₅₀ s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors ^[1] .	
IC ₅₀ & Target	IC ₅₀ : 250 nM (FT) and 520 nM (GGT-1) ^[1]	
In Vitro	FGTI-2734 (1-30 μM; 72 hours) induces CASPASE-3 and PARP cleavage in MiaPaCa2, L3.6pl and Calu6 cells ^[1] . FGTI-2734 (3-30 μM; 72 hours) inhibits both protein prenylation of HDJ2, RAP1A, KRAS and NRAS. FGTI-2734 inhibits KRAS membrane localization in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Apoptosis Analysis ^[1]	
	Cell Line:	MiaPaCa2, L3.6pl and Calu6 cells

Concentration:	1, 3, 10, 30 μ M
Incubation Time:	72 hours
Result:	Induced CASPASE-3 and PARP cleavage in MiaPaCa2, L3.6pl and Calu6 cells.
Western Blot Analysis ^[1]	
Cell Line:	KRAS, HRAS, and NRAS-transformed NIH3T3 cells
Concentration:	3, 10, 30 μ M
Incubation Time:	72 hours
Result:	Inhibited both protein prenylation of HDJ2, RAP1A, KRAS and NRAS.

In Vivo

FGTI-2734 (intraperitoneally; 100 mg/kg/daily for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male SCID-bg mice following injection of MiaPaCa2, L3.6pl, Calu6, A549, H460 and DLD1 cancer cells ^[1]
Dosage:	100 mg/kg
Administration:	Intraperitoneally; daily; for 18 to 25 days
Result:	Inhibited tumor growth in mutant KRAS-dependent tumors.

REFERENCES

[1]. Kazi A, et al. Dual farnesyl and geranylgeranyl transferase inhibitor thwarts mutant KRAS-driven patient-derived pancreatic tumors. Clin Cancer Res. 2019 Jun 21.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA